Cepheid (CPHD) Releases Earnings Results, Beats Expectations By $0.07 EPS

Cepheid (CPHD) reported quarterly earnings results on Thursday, Apr-28-2016. The company said it had a profit of $0.08 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.07. Analysts had a consensus of $0.01. The company posted revenue of $144.80 million in the period, compared to analysts expectations of $140.34 million. The company’s revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS.

Many Wall Street Analysts have commented on Cepheid. Company shares were Reiterated by Canaccord Genuity on Apr 14, 2016 to “Hold”, Firm has raised the Price Target to $ 34 from a previous price target of $29 .Shares were Reiterated by Canaccord Genuity on Feb 3, 2016 to “Hold” and Lowered the Price Target to $ 29 from a previous price target of $34 .Shares were Reiterated by Barclays on Feb 3, 2016 to “Equal Weight” and Lowered the Price Target to $ 36 from a previous price target of $38 .

Cepheid closed down -0.02 points or -0.05% at $36.57 with 3,71,978 shares getting traded on Wednesday. Post opening the session at $36.31, the shares hit an intraday low of $35.44 and an intraday high of $36.85 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Apr 27, 2016, John L Bishop (Chairman of the Board and CEO) sold 110,000 shares at $35.50 per share price. According to the SEC, on Mar 11, 2016, Peter V. Farrell (EVP, Worldwide Commercial Ops) sold 393 shares at $33.01 per share price. On Mar 2, 2016, Robert J Easton (director) sold 12,500 shares at $31.13 per share price, according to the Form-4 filing with the securities and exchange commission.

Cepheid is a molecular diagnostics company. The Company develops manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps including sample preparation DNA amplification and detection. The Company’s systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system which integrates sample preparation in addition to DNA amplification and detection serves reference laboratories and hospital central laboratories to satellite testing locations such as emergency departments and intensive care units within hospitals as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system which integrates DNA amplification and detection to allow rapid analysis of a sample.


Leave a Reply

Cepheid - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cepheid. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.